Cargando…
Thymosin α1 therapy in critically ill patients with COVID-19: A multicenter retrospective cohort study
BACKGROUND: COVID-19 characterized by refractory hypoxemia increases patient mortality because of immunosuppression effects. This study aimed to evaluate the efficacy of immunomodulatory with thymosin α1 for critical COVID-19 patients. METHODS: This multicenter retrospective cohort study was perform...
Autores principales: | Wu, Ming, Ji, Jing-jing, Zhong, Li, Shao, Zi-yun, Xie, Qi-feng, Liu, Zhe-ying, Wang, Cong-lin, Su, Lei, Feng, Yong-wen, Liu, Zhi-feng, Yao, Yong-ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7409727/ https://www.ncbi.nlm.nih.gov/pubmed/32795897 http://dx.doi.org/10.1016/j.intimp.2020.106873 |
Ejemplares similares
-
The effect of thymosin α1 on mortality of critical COVID-19 patients: A multicenter retrospective study
por: Sun, Qin, et al.
Publicado: (2021) -
Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort study
por: Shao, Ziyun, et al.
Publicado: (2020) -
Risk factors for mortality in critically ill patients with COVID-19: a multicenter retrospective case-control study
por: Gao, Jinghua, et al.
Publicado: (2021) -
Production of N(α)-acetylated thymosin α1 in Escherichia coli
por: Ren, Yuantao, et al.
Publicado: (2011) -
Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study
por: Liu, Jiao, et al.
Publicado: (2021)